Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

AIDS

Volumn 18, Issue 3, 2004, Pages 572-574

  Winston, Alan ^a   Pozniak, Anton ^a   Smith, Nicola ^a   Fletcher, Carl ^a   Mandalia, Sundhiya ^a   Parmar, Darmishta ^a   Gibbons, Sarah ^b   Back, David ^b   Gazzard, Brian ^a   Nelson, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; EFAVIRENZ; NEVIRAPINE;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; PLASMA HALF LIFE; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; OXAZINES; VIRAL LOAD;

EID: 12144286267     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00029     Document Type: Article

References (7)

1. Brook G. BHIVA audit report and updates. In: BHIVA 9th Annual Conference. Manchester, UK, 2003.
2. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HiV-1 infection in adults. N Engl J Med 1999; 341:1865-1873.
3. Dona C, Soriano V, Barreiro P, Jimenez-Nachera I, Gonzalez-Lahoz J,. Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program. Med Clin (Barc) 2000; 115:337-338.
4. Staszewski S, Gallant J, Pozniak A, Suleiman IMAH, Jesus ED, Koenig E, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. In: 14th International AIDS Conference. Barcelona 2002 [Abstract 17].
5. Veldkamp AL, Harris M, Montaner JS, Moyle C, Gazzard B, Youle M, et al. The steady-state pharmacokinetics of efavirenz and nevirapineine when used in combination in HIV-1 infected persons. J Infect Dis 2001; 184:37-42.
6. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 (Suppl.5):S171-S181.
7. Moyle C, Gazzard B. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002; 16:1086-1087.